Humacyte Aktie News

While Nancy Pelosi often dominates discussions on insider trades in the US, the year 2024 has seen a shift in focus to her Republican counterpart, Tommy Tuberville. His series of trades, particularly notable for their insider nature, have sparked significant interest.

Humacyte's stock price has recently been on an impressive bull run, jumping from $4.50 to $6.50 after management announced Q1 2024 earnings. The company's market cap valuation is currently around $765 million - I believe this could rise >$1bn if the company secures a first commercial approval this year, as is likely. Humacyte focuses on regenerative medicine technology, specifically bioengineer...

DURHAM, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, Dale Sander, Chief Financial Officer, and B.J. Scheessele, Chief Commercial Officer, wil...

Humacyte, Inc. (NASDAQ:HUMA ) Q1 2024 Earnings Conference Call May 10, 2024 8:00 AM ET Company Participants Tom Johnson - Investor Relations, LifeSci Advisors Laura Niklason - Founder, President, Chief Executive Officer Dale Sander - Chief Financial Officer, Chief Corporate Development Officer, Treasurer Heather Prichard - Chief Operating Officer Conference Call Participants Ryan Zimmerman - BT...

-Biologics License Application (BLA) for HAV™ Accepted by FDA- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August 10, 2024- -Raised approximately $43 million in net proceeds from public offering of common stock- -Conference call and live webcast at 8:00 a.m. ET today- DURHAM, N.C.

DURHAM, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the first quarter ended March 31, 2024, on Friday, May 10, 2024. Management will host a webcast and conference call at 8:00 a.m. ET to provide a cor...

Members of the U.S. Senate and Congress are no strangers to making highly lucrative and frequently unorthodox stock picks, with their timing and success rates being such that many firmly believe they are acting on insider information.

U.S. Senator Tommy Tuberville disclosed the purchase of Humacyte Inc. (NASDAQ: HUMA) stocks on April 15. Four days later, HUMA's stock saw a 43% price surge, raising alerts of suspicious trading activity.